Zura Bio Ltd

ZURA

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (Tibulizumab Dose A): Nov 2026. Short interest: 13.1% of float.

BiotechnologyCEO: Sandeep C. KulkarniIPO: 2023Website ↗

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Zura Bio Ltd

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research